Pfizer said on October 27, 2026, that its Phase 3 Elrexfio trial met its primary progression-free survival endpoint in patients with relapsed or refractory multiple myeloma. Median progression-free survival had not yet been reached.
Key Takeaways
- The MagnetisMM-32 trial enrolled 523 patients with the blood cancer.
- Pfizer reported that many participants remained progression-free.
Elrexfio trial meets primary endpoint
The MagnetisMM-32 study evaluated Elrexfio, also known as elranatamab, in patients whose multiple myeloma had returned or was resistant to treatment.
Progression-free survival measures how long patients live without their disease worsening. A median that has not yet been reached means the available follow-up was not sufficient to establish that midpoint.
What the reported results leave open
The available information does not specify the size of the treatment effect, a comparator or safety results. It also does not establish a timetable for a regulatory submission.
The announcement adds to Pfizer’s oncology pipeline, which includes cancer therapies Ibrance and Xtandi.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
Comments
Be respectful. No spam, impersonation or private credentials. Ordinary posts and comments appear immediately; suspicious links are held for review.
Please wait…